

# Sonothrombolysis in ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Final Results from the First Randomized Study in Humans

**Wilson Mathias, Jr<sup>1</sup>**, Jeane M Tsutsui<sup>1</sup>, Bruno G Tavares<sup>1</sup>, Agostina Fava<sup>2</sup>, Miguel O D Aguiar<sup>1</sup>, Bruno C Borges<sup>1</sup>, Mucio T Oliveira Jr<sup>1</sup>, Alexandre Soeiro<sup>1</sup>, Jose C Nicolau<sup>1</sup>, Henrique B Ribeiro<sup>1</sup>, Hsu Pochiang<sup>1</sup>, João C N Sbano<sup>1</sup>, Abdul Morad<sup>2</sup>, Andrew Goldsweig<sup>2</sup>, Carlos E Rochitte<sup>1</sup>, Bernardo B C Lopes<sup>1</sup>, José A F Ramirez<sup>1</sup>, Roberto Kalil Filho<sup>1</sup>, Thomas R Porter<sup>2</sup>.

<sup>1</sup> Heart Institute (InCor), The University of São Paulo Medical School, Brazil

<sup>2</sup> Cardiology Department of The University of Nebraska Medical Center, USA



State of São Paulo, Government Agency  
"BRAZILIAN NIH"






Heart Institute (InCor)  
University of São Paulo Medical School  
São Paulo, Brazil

UNIVERSITY OF  
**Nebraska**  
Medical Center

Theodore F. and Claire M.  
Hubbard Family Foundation

Late Breaking Clinical Trials Session, ACC19, March 17, 2019


# BACKGROUND




**Occluded Graft**



**Low MI Imaging  
Small channels despite  
Graft Occlusion**



**Increase in Channels size  
After Intermitent  
High MI US**



*Tsutsui JM et al. Treatment of Deeply Located Acute Intravascular Thrombi With Therapeutic Ultrasound Guided by Diagnostic Ultrasound and Intravenous Microbubbles. J Ultrasound Med. 2006 Sep;25(9):1161-8.*

# **Coronary Reperfusion Therapies in 2019**

## **Drawbacks**




*Fibrinolysis: Major Haemorrhagic Complications in ~ 17%*



*Recanalization rates ~ 60% cases when patients present within 4h of pain*



*Fibrinolysis and PCI are Available in Brazil to only ~40% of patients*



*Even with PCI, microvascular occurs in ~35 % of Cases*

*Aggarwal S et.al. J Am Soc Echocardiogr 2018;31:674-82*  
*Nicoli G et al. Am Coll Cardiol 54:281-92, 2009*  
*Nicolau JC et al. Arq Bras Cardiol. 105(2):1-105, 2015*




# ***Study Design***



*Prospective, single-center, two arm randomized study*



*Patients with 1<sup>st</sup> ST elevation AMI*



*May 2014 – July 2018*



**Research Project # 2010/52114-1**  
**Final IRB Approval # 342.799 (07/08/2013)**  
**Clinical Trials.gov # NCT02410330**

# OBJECTIVES



**1** – *To determine the safety and feasibility of sonothrombolysis in humans during acute STEMI in **100 patients***



**2** – *To determine the potential efficacy of sonothrombolysis in achieving early infarct vessel patency and restoring left ventricular systolic function by reducing MI size*


# Study Workflow

Emergency Room

Interventional Lab

Imaging Lab

Follow-up



**Arrival at night**  
**Weekends / Holidays**

**Reference Group (n = 203)**

**Door to balloon time**


**Primary PCI**

• Clinical data

• ARR pre-PCI





# Patient Selection




# Elektrocardiogram, Biomarkers and Angiography

- ✓ ST segment resolution as a % or  $\geq 50\%$  ST resolution from baseline to Post sonolysis pre PCI and at the end of the second sonolysis (\*).



- ✓ Cardiac specific troponin and creatinine kinase MB fraction (MB-CK) every 3 hours for 18 hours.

Closed artery – TIMI 0 and 1



Opened artery – TIMI 2 and 3



**Interpretation: UNMC,  
Nebraska**



# Echocardiography and cMRI



## cMRI by Achieva 1.5T Scanner

- ✓ Early (EGE) and Late gadolinium enhancement (LGE) images were obtained at 2 and 10 minutes following injection of 0.2 mmol/Kg Gadolinium. Interpretation: UNMC - Nebraska



## Echocardiography by IE33 – Philips Medical Systems



- ✓ A score of 1: normal perfusion; 2: >4 second delay; 3: absent replenishment at 10 seconds post high MI impulse (MVO).
- ✓ EDV, ESV and Ejection Fraction were computed by contrast images using Simpson's Rule.
- ✓ Interpretation: two experienced cardiologists blinded to treatment assignment (InCor, Brazil)



Botker HE et al. J Cardiovas Magn Reson., 14;68, 2012.  
Lang RM et al. J Am Soc Echocardiogr 28:1–39, 2015.  
Porter TR et al. 31, 241-274, 2018.

# Statistics

- ✓ Based on pilot data (\*), we anticipated randomizing 100 patients to achieve statistical significance ( $p < 0.05$  using unpaired one-tailed  $t$  testing for continuous variables).
- ✓ Data were analyzed for possible confounders




- ✓ Primary outcomes: rate of ST segment resolution and angiographic patency prior to PCI as continuous and dichotomous variable.
- ✓ Secondary outcomes: Infarct size by CMRI and microvascular flow, LVEF and Myocardial Perfusion post PCI, one week and six months.
- ✓ Differences were compared between groups at specific time points, and no adjustments were made for multiple comparisons over time.

# Demographic Variables

	Control Group	Therapy Group	Reference Group	
Variable	n= 50	n = 50	n = 203	p Value
Age (years)	59±11	59±10	59+11	0.96 <sup>(1)</sup>
Gender (male)	40 (80%)	32 (64%)	148 (73%)	0.20 <sup>(2)</sup>
Weight (kg)	77±16	74±16	76+13	0.65 <sup>(1)</sup>
BSA (m <sup>2</sup> )	1.86 + 0.22	1.82 + 0.22	1.82 + 0.19	0.41 <sup>(1)</sup>
Diabetes	11 (22%)	21 (42%)	67 (33%)	0.10 <sup>(2)</sup>
Hypertension	28 (56%)	28 (56%)	118 (58%)	0.95 <sup>(2)</sup>
Hyperlipidemia	15 (30%)	20 (40%)	55 (27%)	0.20 <sup>(2)</sup>
Smoking	20 (40%)	24 (48%)	70 (34%)	0.20 <sup>(2)</sup>
Medication in use				
Statin	14 (28%)	19 (38%)	21 (10%)	<0.001 <sup>(2)</sup>
Beta blocker	5 (10%)	14 (28%)	27 (13%)	0.019 <sup>(2)</sup>
Aspirin	50 (100%)	48 (96%)	202 (99%)	0.14 <sup>(3)</sup>
Nitrate	25 (50%)	27 (54%)	95 (47%)	0.64 <sup>(2)</sup>
Calcium channel Blocker	4 (8%)	5 (10%)	14 (7%)	0.72 <sup>(3)</sup>
STEMI arterial territory				
LAD	26 (52%)	26 (52%)	90 (44%)	0.83 <sup>(2)</sup>
RCA	14 (28%)	17 (34%)	84 (41%)	
LCX	10 (20%)	7 (14%)	29 (14%)	

Variables expressed as mean ± standard deviation or number (%). (1) Analysis of variance; (2) Chi- square test; (3) Fisher Exact test.

# Door to Balloon Time




Fisher Exact test



# Angiographic Recanalization Rate Pre PCI


$p < 0.001$  between groups




*Chi Square X2 test*

# Change in Perfusion Score # Segs MVO (Baseline - Post PCI)

Perfusion Score (Echo)



# of Segments with MVO (Echo)



Control Group







Therapy Group

\* Paired Student T test

\*\* Unpaired Student T test

\*\*\* Chi Square test

# ST Segment Resolution and Peak Troponin/MB-CK Values



(\*) Mann-Whitney test; (\*\*) Student T test.

## ***Clinical Case # 76***

### *Randomized to Therapy Group*



*CAF, 52y/o Male*



*Hypertensive*



*Dyslipidemia*




*Continuous chest pain (9/10 Scale) for ~1:45h*




# Clinical Case # 76

*EKG at arrival*




*EKG post PCI*



*Beginning of Sonothrombolysis*



*At 12 minutes of Sonothrombolysis*



*Echo post PCI*




**LVEF 29%**


# Clinical Case # 76

*Coronary Angiography*



*Before PCI*



*Post PCI*





*72h cMRI*



*72h MRI demonstrating 4 Chamber View and a focal perfusion defect on first pass in mid anterior wall segment*

# Infarct Size by MRI and LVEF by Echo




**Controls**  
(PCI only Group)

**Therapy**  
(High MI+PCI Group)

*Mann Whitney test*

## *Follow-up – EF < 30%*

Qualified for Automatic Implantable Cardioverter Defibrillator



\* Fisher Exact test



## **Sonothrombolysis in ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Final Results from the First Randomized Study in Humans**

1 – Sonothrombolysis in humans is safe and feasible in patients with STEMI

**2 – Sonothrombolysis is efficacious in achieving early infarct vessel patency, microvascular flow, reducing infarct size and consequently restoring left ventricular systolic function**

3- A Phase III multicenter clinical trial is warranted with focus on earlier sonothrombolysis at point of patients care

## Sonothrombolysis in ST-segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Wilson Mathias, Jr, MD, PhD,<sup>a</sup> Jeane M. Tsutsui, MD, PhD,<sup>a</sup> Bruno G. Tavares, MD,<sup>a</sup> Agostina M. Fava, MD,<sup>b</sup> Miguel O.D. Aguiar, MD,<sup>a</sup> Bruno C. Borges, MD,<sup>a</sup> Mucio T. Oliveira, Jr, MD, PhD,<sup>a</sup> Alexandre Soeiro, MD, PhD,<sup>a</sup> Jose C. Nicolau, MD, PhD,<sup>a</sup> Henrique B. Ribeiro, MD, PhD,<sup>a</sup> Hsu Pochiang, MD,<sup>a</sup> João C.N. Sbrano, MD, PhD,<sup>a</sup> Abdulrahman Morad, MD,<sup>c</sup> Andrew Goldsweig, MD,<sup>b</sup> Carlos E. Rochitte, MD, PhD,<sup>a</sup> Bernardo B.C. Lopes, MD,<sup>a</sup> José A.F. Ramirez, MD, PhD,<sup>a</sup> Roberto Kalil Filho, MD, PhD,<sup>a</sup> Thomas R. Porter, MD,<sup>b</sup> The Microvascular Recovery with Ultrasound in Acute Myocardial Infarction (MRUSMI) Investigators

### ABSTRACT

**BACKGROUND** Pre-clinical studies have demonstrated that high mechanical index (MI) impulses from a diagnostic ultrasound transducer (DUS) during an intravenous microbubble infusion (Sonothrombolysis) can restore epicardial and microvascular flow in acute ST-segment elevation myocardial infarction (STEMI).

**OBJECTIVE** We tested the clinical effectiveness of sonothrombolysis in patients with STEMI.

**METHODS** Patients with their first STEMI were prospectively randomized to either DUS-guided high MI impulses during an intravenous ultrasound agent infusion prior to, and following, emergent percutaneous coronary intervention (PCI), or to a control group that received PCI only (n=50 in each group). A reference first STEMI group (n=203) who arrived outside the randomization window was also analyzed. Angiographic recanalization prior to PCI, ST-segment resolution, infarct size (IS) by magnetic resonance imaging, and systolic function (LVEF) at six months were compared.


**RESULTS** ST-segment resolution occurred in 16 (32%) high MI PCI versus 2(4%) PCI only patients prior to PCI, and angiographic recanalization was 48% in high/MI PCI versus 20% in PCI only and reference groups (p<0.001). IS was reduced (29±22 grams high MI/PCI versus 40±20 grams PCI only; p=0.026). LVEF was not different between groups before treatment (44±11% versus 43±10%), but increased immediately after PCI in the high MI/PCI group (p=0.03), and remained higher at six months (p=0.015). Need for implantable defibrillator (LVEF≤30%) was reduced in the high MI/PCI group (5% versus 18% PCI only; p=0.045).

**CONCLUSIONS** Sonothrombolysis added to PCI improves recanalization rates and reduces infarct size, resulting in sustained improvements in systolic function after STEMI.

**TRIAL REGISTRATION** Clinical [Trials.gov](https://www.trials.gov) # NCT02410330. (J Am Coll Cardiol 2019) © 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.

Email for correspondence: [wmathias@incor.usp.br](mailto:wmathias@incor.usp.br)

<sup>a</sup>Heart Institute (InCor)- University of São Paulo, Medical School, São Paulo, Brazil; <sup>b</sup>University of Nebraska Medical Center, Omaha, NE; and the <sup>c</sup>University of Kansas Medical Center, Kansas City, KS. **IRB Approval** # 342.799 (07/08/2013)



“This is not the end. This is not even the beginning of the end, but perhaps, it is the end of the beginning”

**Winston Churchill**  
2<sup>nd</sup> Battle of El Alamein